Maia Biotechnology Inc (MAIA) Stock Analysis
Verdict: AVOID
Pre-revenue clinical biotech MAIA faces ongoing share dilution to fund Phase 3 burn, offsetting positive insider purchases.
Investment score: 34/100
Analysis as of
Is Maia Biotechnology Inc stock worth reviewing? AI model thesis
From the model's perspective, MAIA Biotechnology is a pre-revenue clinical biotech with a narrow 10-month cash runway ($27.6M cash vs $6.75M quarterly burn), forcing continuous equity dilution that negates encouraging Phase 2/3 THIO trial data.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 85/100 (weight 10%)
- Analyst Consensus: 35/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Maia Biotechnology Inc opportunities and risks
What speaks for MAIA
- Pivotal Phase 3 THIO-104 trial progress in 3L non-small cell lung cancer
What speaks against MAIA
- Quarterly operating cash burn of $6.75M limits cash runway to roughly 10 months
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MAIA | n/a | 0.0x | n/a | 0.0% | 0.0% | -28.3% |
| FBIO | 0.8x | 1.2x | n/a | 62.5% | 163.3% | 150.9% |
| OSTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -23.0% |
| SERA | n/a | 1137.5x | n/a | -150.0% | -47475.7% | -35.3% |
| ALDX | n/a | 0.0x | n/a | 0.0% | 0.0% | -26.9% |
| CNTB | n/a | 27.4x | n/a | 100.0% | -1763.4% | -39.6% |
| Peer median | n/a | 1.2x | n/a | 0.0% | 0.0% | -26.9% |
Frequently asked questions about Maia Biotechnology Inc (MAIA)
Is MAIA stock a good investment?
The cached TradeMates AI model rates Maia Biotechnology Inc as AVOID with an investment score of 34/100. From the model's perspective, MAIA Biotechnology is a pre-revenue clinical biotech with a narrow 10-month cash runway ($27.6M cash vs $6.75M quarterly burn), forcing continuous equity dilution that negates encouraging Phase 2/3 THIO trial data. This is algorithmic model output, not personal investment advice.
Is MAIA stock a buy?
The TradeMates model verdict for MAIA is AVOID with an investment score of 34/100. Treat this as a model signal to review, not a personal buy recommendation.